These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22296182)

  • 1. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?
    Fozza C; Longinotti M
    Eur J Haematol; 2012 May; 88(5):380-7. PubMed ID: 22296182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immune landscape of myelodysplastic syndromes.
    Fozza C; Crobu V; Isoni MA; Dore F
    Crit Rev Oncol Hematol; 2016 Nov; 107():90-99. PubMed ID: 27823655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of T-cells in the pathogenesis of myelodysplastic syndromes: passengers and drivers.
    Fozza C; Longinotti M
    Leuk Res; 2013 Feb; 37(2):201-3. PubMed ID: 23218025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.
    Kiladjian JJ; Visentin G; Viey E; Chevret S; Eclache V; Stirnemann J; Bourhis JH; Chouaib S; Fenaux P; Caignard A
    Haematologica; 2008 Mar; 93(3):381-9. PubMed ID: 18268282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The research update on cellular immune abnormality in myelodysplastic syndrome--review].
    Xu F; Liu T
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):673-7. PubMed ID: 14706159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the immune system in myelodysplasia: implications for therapy.
    Sloand EM; Rezvani K
    Semin Hematol; 2008 Jan; 45(1):39-48. PubMed ID: 18179968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Th17 and Foxp3(+) T regulatory cell dynamics and distribution in myelodysplastic syndromes.
    Bouchliou I; Miltiades P; Nakou E; Spanoudakis E; Goutzouvelidis A; Vakalopoulou S; Garypidou V; Kotoula V; Bourikas G; Tsatalas C; Kotsianidis I
    Clin Immunol; 2011 Jun; 139(3):350-9. PubMed ID: 21444247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
    Aggarwal S; van de Loosdrecht AA; Alhan C; Ossenkoppele GJ; Westers TM; Bontkes HJ
    Br J Haematol; 2011 Jun; 153(5):568-81. PubMed ID: 21488861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplasia and autoimmunity.
    Giannouli S; Kanellopoulou T; Voulgarelis M
    Curr Opin Rheumatol; 2012 Jan; 24(1):97-102. PubMed ID: 22157417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic abnormalities in myelodysplastic syndromes.
    Hamblin T
    Hematol Oncol Clin North Am; 1992 Jun; 6(3):571-86. PubMed ID: 1613007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant.
    Fozza C
    Crit Rev Oncol Hematol; 2019 Jan; 133():112-119. PubMed ID: 30661647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes.
    Boula A; Voulgarelis M; Giannouli S; Katrinakis G; Psyllaki M; Pontikoglou C; Markidou F; Eliopoulos GD; Papadaki HA
    Clin Cancer Res; 2006 May; 12(10):3099-108. PubMed ID: 16707608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes.
    Zhao ZG; Xu W; Yu HP; Fang BL; Wu SH; Li F; Li WM; Li QB; Chen ZC; Zou P
    Cancer Lett; 2012 Apr; 317(2):136-43. PubMed ID: 22240014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schmid C; Schweiger C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):75-85. PubMed ID: 16091127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting immune dysregulation in myelodysplastic syndromes.
    Olnes MJ; Sloand EM
    JAMA; 2011 Feb; 305(8):814-9. PubMed ID: 21343581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective cytotoxicity of T lymphocytes in myelodysplastic syndrome.
    Cukrová V; Neuwirtová R; Dolezalová L; Belicková M; Bartůnková J; Jonásová A; Cermák J; Homolková H; Malíková I
    Exp Hematol; 2009 Mar; 37(3):386-94. PubMed ID: 19136196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunosuppressive treatment of the myelodysplastic syndrome].
    Larsen MS; Hasselbalch HC
    Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-induced cytopenia: bone marrow failure syndrome.
    Kondo Y; Molldrem JJ
    Curr Hematol Rep; 2004 May; 3(3):178-83. PubMed ID: 15087065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure.
    Maciejewski JP; Hibbs JR; Anderson S; Katevas P; Young NS
    Exp Hematol; 1994 Oct; 22(11):1102-10. PubMed ID: 7925777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.